Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

Ceasing Amniocentesis

A noninvasive test for genetic defects in fetuses has reached human clinical studies.

Pregnant women seeking prenatal tests for genetic defects face difficult choices. Either they accept less-than-reliable blood tests or ultrasound interpretations that leave them anxious and guessing, or they choose amniocentesis, which punctures the embryonic sac and has a small risk of causing miscarriage.

Researchers have long envisioned the day when a test of the mother’s blood or urine could conclusively detect a genetic defect in her baby. Xenomics, a New York City-based biotech firm, is now conducting the first clinical studies of a urine test that, it says, can detect Down syndrome in the fetus.

A pregnant woman’s blood and urine both contain fragments of her fetus’s DNA. Xenomics’ advance is based on its discovery of specific DNA markers, called methylation sites, that may indicate whether a fetus has a chromosome abnormality related to Down syndrome. The Xenomics test under development uses standard DNA amplification technology to spot the markers in a urine sample.

This story is part of our December 2005/January 2006 Issue
See the rest of the issue
Subscribe

Xenomics is now conducting human clinical studies with two U.S. hospitals and hopes to submit the test for U.S. Food and Drug Administration approval in mid-2007.

The basic technique could work for certain other genetic disorders; ones that result from a mutation in a single gene are likely to have their own methylation markers, researchers say. Farideh Bischoff, a reproductive geneticist at Baylor College of Medicine in Houston, says scientists have identified the mutations that cause cystic fibrosis, Huntington’s disease, beta-thalassemia, and other ailments.

Although DNA tests for these diseases have been developed, says Bischoff, they require full strands of DNA found only in cells, not just the fragments that can be most easily found in maternal blood or urine. “Clinical trials using DNA fragments haven’t been pursued to validate [them],” she says. But Bischoff predicts clinical trials will begin within five years and lead to new prenatal tests. “I think noninvasive testing is going to take over,” she says.

Tech Obsessive?
Become an Insider to get the story behind the story — and before anyone else.

Subscribe today
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.